Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1969 1
1984 1
1986 1
1989 1
1990 1
1991 1
1992 1
1993 4
1994 2
1995 7
1997 1
1999 2
2000 6
2001 6
2002 8
2003 2
2004 2
2005 8
2006 3
2007 5
2008 4
2009 4
2010 1
2011 1
2013 2
2014 3
2015 3
2016 4
2017 3
2018 1
2019 8
2020 8
2021 1
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hopkins re[au] (42 results)?
Early Positron Emission Tomography Response-Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial.
André MPE, Girinsky T, Federico M, Reman O, Fortpied C, Gotti M, Casasnovas O, Brice P, van der Maazen R, Re A, Edeline V, Fermé C, van Imhoff G, Merli F, Bouabdallah R, Sebban C, Specht L, Stamatoullas A, Delarue R, Fiaccadori V, Bellei M, Raveloarivahy T, Versari A, Hutchings M, Meignan M, Raemaekers J. André MPE, et al. Among authors: re a. J Clin Oncol. 2017 Jun 1;35(16):1786-1794. doi: 10.1200/JCO.2016.68.6394. Epub 2017 Mar 14. J Clin Oncol. 2017. PMID: 28291393 Clinical Trial.
Purpose Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early response evaluation with positron emission tomography (PET) scan may improve selection of patients who need reduced or more intensive treatmen …
Purpose Patients who receive combined modality treatment for stage I and II Hodgkin lymphoma (HL) have an excellent outcome. Early re …
Hiv and Lymphoma: from Epidemiology to Clinical Management.
Re A, Cattaneo C, Rossi G. Re A, et al. Mediterr J Hematol Infect Dis. 2019 Jan 1;11(1):e2019004. doi: 10.4084/MJHID.2019.004. eCollection 2019. Mediterr J Hematol Infect Dis. 2019. PMID: 30671210 Free PMC article. Review.
Patients infected with human immunodeficiency virus (HIV) are at increased risk for developing both non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL). Even if this risk has decreased for NHL after the introduction of combination antiretroviral therapy (cART), …
Patients infected with human immunodeficiency virus (HIV) are at increased risk for developing both non-Hodgkin's lymphoma (NHL) and …
Molecular pathogenesis of Hodgkin's lymphoma.
Re D, Küppers R, Diehl V. Re D, et al. J Clin Oncol. 2005 Sep 10;23(26):6379-86. doi: 10.1200/JCO.2005.55.013. J Clin Oncol. 2005. PMID: 16155023 Review.
According to the WHO classification, Hodgkin's lymphoma (HL) is subdivided into a classical variant and a nodular lymphocyte predominant variant which are characterized by the presence of Hodgkin's and Reed-Sternberg (H-RS) cells or lymphocytic and histiocytic (L&am …
According to the WHO classification, Hodgkin's lymphoma (HL) is subdivided into a classical variant and a nodular lymphocyte predomin …
Genetic instability in Hodgkin's lymphoma.
Re D, Zander T, Diehl V, Wolf J. Re D, et al. Ann Oncol. 2002;13 Suppl 1:19-22. doi: 10.1093/annonc/13.s1.19. Ann Oncol. 2002. PMID: 12078897 Free article. Review.
Genetic instability is a characteristic feature of the malignant Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin's lymphoma and the lymphocytic and histiocytic (L&H) cells in lymphocyte predominant Hodgkin's lymphoma. Genetic instability can b …
Genetic instability is a characteristic feature of the malignant Hodgkin and Reed-Sternberg (HRS) cells in classical Hodgkin's …
Epidemiology and etiology of Hodgkin's lymphoma.
Thomas RK, Re D, Zander T, Wolf J, Diehl V. Thomas RK, et al. Among authors: re d. Ann Oncol. 2002;13 Suppl 4:147-52. doi: 10.1093/annonc/mdf652. Ann Oncol. 2002. PMID: 12401681 Free article. Review. No abstract available.
A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma.
Carlo-Stella C, Zinzani PL, Sureda A, Araújo L, Casasnovas O, Carpio C, Yeh SP, Bouabdallah K, Cartron G, Kim WS, Cordoba R, Koh Y, Re A, Alves D, Chamuleau M, Le Gouill S, López-Guillermo A, Moreira I, van der Poel MWM, Abbadessa G, Meng R, Ji R, Lépine L, Saleem R, Ribrag V. Carlo-Stella C, et al. Among authors: re a. Hematol Oncol. 2023 Feb;41(1):108-119. doi: 10.1002/hon.3089. Epub 2022 Oct 31. Hematol Oncol. 2023. PMID: 36251503 Free PMC article. Clinical Trial.
In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in combination with cemiplimab (Cemi, anti-programmed death-1 [PD-1] receptor antibody; Isa + Cemi) in patients with classic Hodgkin lympho …
In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in com …
Hematopoietic cell transplantation for plasmablastic lymphoma: a review.
Al-Malki MM, Castillo JJ, Sloan JM, Re A. Al-Malki MM, et al. Among authors: re a. Biol Blood Marrow Transplant. 2014 Dec;20(12):1877-84. doi: 10.1016/j.bbmt.2014.06.009. Epub 2014 Jun 16. Biol Blood Marrow Transplant. 2014. PMID: 24946718 Free article. Review.
Plasmablastic lymphoma (PBL) is recognized by the World Health Organization as a very aggressive subtype of non-Hodgkin lymphoma. It was initially described in the setting of human immunodeficiency virus (HIV) infection, but it has since been identified in immunocompetent …
Plasmablastic lymphoma (PBL) is recognized by the World Health Organization as a very aggressive subtype of non-Hodgkin lymphoma. It …
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma.
Federico M, Fortpied C, Stepanishyna Y, Gotti M, van der Maazen R, Cristinelli C, Re A, Plattel W, Lazarovici J, Merli F, Specht L, Schiano de Colella JM, Hutchings M, Versari A, Edeline V, Stamatoulas A, Girinsky T, Ricardi U, Aleman B, Meulemans B, Tonino S, Raemaekers J, André M. Federico M, et al. Among authors: re a. J Clin Oncol. 2024 Jan 1;42(1):19-25. doi: 10.1200/JCO.23.01745. Epub 2023 Nov 15. J Clin Oncol. 2024. PMID: 37967311 Clinical Trial.
Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The primary analysis of the Early positron emission tomography (ePET) Response-Adapted Treatment …
Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the p …
Hodgkin's Lymphoma in Older Patients: an Orphan Disease?
Thyss A, Saada E, Gastaud L, Peyrade F, Re D. Thyss A, et al. Among authors: re d. Mediterr J Hematol Infect Dis. 2014 Jul 1;6(1):e2014050. doi: 10.4084/MJHID.2014.050. eCollection 2014. Mediterr J Hematol Infect Dis. 2014. PMID: 25045458 Free PMC article. Review.
Hodgkin Lymphoma HL can be cured in the large majority of younger patients, but prognosis for older patients, especially those with advanced-stage disease, has not improved substantially. ...Patients over 60y with early-stage disease received three cycles plu …
Hodgkin Lymphoma HL can be cured in the large majority of younger patients, but prognosis for older patients, especially those with a …
Role of Rituximab Addition to First-line Chemotherapy Regimens in Nodular Lymphocyte-predominant Hodgkin Lymphoma: A Study by Fondazione Italiana Linfomi.
Gotti M, Sciarra R, Pulsoni A, Merli F, Luminari S, Zerbi C, Trentin L, Re A, Rusconi C, Viviani S, Rossi A, Cocito F, Botto B, Meli E, Pinto A, Dogliotti I, Gini G, Puccini B, Ricci F, Nassi L, Fabbri A, Liberati AM, Merli M, Filippi AR, Bonfichi M, Zoboli V, Tartaglia G, Annechini G, D'Elia GM, Del Giudice I, Alvarez I, Visentin A, Pravato S, Dalceggio D, Pagani C, Ferrari S, Cristinelli C, Lazic T, Ferretti VV, Ricardi U, Arcaini L. Gotti M, et al. Among authors: re a. Hemasphere. 2023 Apr 4;7(4):e837. doi: 10.1097/HS9.0000000000000837. eCollection 2023 Apr. Hemasphere. 2023. PMID: 37034003 Free PMC article.
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity whose neoplastic cells retain a B-cell phenotype with expression of CD20. Radiotherapy is recommended for favorable stage IA disease while for other stages guidelines suggest therapeutic strate …
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a rare entity whose neoplastic cells retain a B-cell phenotype with expres …
110 results